Articles

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Mayo Clinic, Scottsdale, AZ, USA
Stanford Cancer Institute, Stanford, CA, USA
Incyte Corporation, Wilmington, DE, USA
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Washington University School of Medicine, St. Louis, MO, USA
Frankston Hospital and Department of Clinical Haematology, Monash University, Frankston, Australia
Division of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
Saint Agnes Cancer Institute, Baltimore, MD, USA
Weill Cornell Medical Center, New York, NY, USA
University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA
Emory University School of Medicine, Atlanta, GA, USA
Birmingham Hematology and Oncology, Birmingham, AL, USA
Duke University Health System, Durham, NC, USA
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
Cancer Care Centers of South Texas/US Oncology, San Antonio, TX, USA
UCLA Division of Hematology/Oncology, Los Angeles, CA, USA
Columbia Presbyterian Medical Center, New York, NY, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Vol. 98 No. 12 (2013): December, 2013 https://doi.org/10.3324/haematol.2013.092155